Department of Pathology and Laboratory Medicine, the Ottawa Hospital and Eastern Ontario Regional Laboratory Association and University of Ottawa, ON, Canada.
Department of Laboratory Hematology, Flow Cytometry Laboratory, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Cytometry B Clin Cytom. 2018 Mar;94(2):230-238. doi: 10.1002/cyto.b.21402. Epub 2016 Aug 18.
We have evaluated the frequency of lymphoproliferative disorders with more than one aberrant population of monotypic B-cells detected during routine hematopathological diagnostics.
2600 samples peripheral (blood, bone marrow, fine-needle aspirate, lymph node, and pleural fluid cell suspensions) were analyzed using a 10-color B-cell panel and a 10-color T-cell panel. A 10-color plasma cell/lymphoplasmacytic panel was performed when appropriate.
790/2600 samples (30%) showed at least one aberrant B-cell population and 27(1%) showed an aberrant T-cell population. 41/790 samples (5.1%) showed two aberrant B-cell populations. Thirteen patients had two B-cell populations with different surface immunoglobulin restriction (one kappa+ and one lambda+), most with B-cell chronic lymphocytic leukemia-related phenotype. Five cases showed two B-cell populations with the same light chain restriction but distinctly different immunophenotypes. In 23 cases, two populations had the same light chain restriction and differed by expression of one or 2 markers, thus, a possibility of intraclonal differentiation could not be excluded. Cases with possible intraclonal differentiation had a significantly higher proportion of aberrant B-cells than those with two coexisting aberrant B-cell populations (49.9% vs. 27.7%, p = 0.008). In only one sample one population of clonal B-cell and one clonal T-cell population with large granular lymphocyte related phenotype were found.
Using our panels 5.1% of cases with lymphoproliferative disorder-associated aberrant findings show two aberrant (clonal) lymphoid and/or plasma cell populations. © 2016 International Clinical Cytometry Society.
我们评估了在常规血液病理学诊断中检测到超过一种异常单型 B 细胞群体的淋巴增生性疾病的频率。
使用 10 色 B 细胞面板和 10 色 T 细胞面板分析了 2600 例外周（血液、骨髓、细针抽吸、淋巴结和胸腔积液细胞悬浮液）样本。在适当的情况下进行了 10 色浆细胞/淋巴浆细胞面板检测。
790/2600 例样本（30%）显示至少一种异常 B 细胞群体，27 例（1%）显示异常 T 细胞群体。41/790 例样本（5.1%）显示两种异常 B 细胞群体。13 例患者有两种不同表面免疫球蛋白限制的 B 细胞群体（一种kappa+和一种 lambda+），大多数具有 B 细胞慢性淋巴细胞白血病相关表型。5 例显示两种具有相同轻链限制但明显不同免疫表型的 B 细胞群体。在 23 例中，两种群体具有相同的轻链限制，并且在一个或 2 个标志物的表达上有所不同，因此不能排除克隆内分化的可能性。有潜在克隆内分化的病例异常 B 细胞的比例明显高于具有两种共存异常 B 细胞群体的病例（49.9%对 27.7%，p=0.008）。在仅一个样本中，发现一种克隆 B 细胞群体和一种与大颗粒淋巴细胞相关表型的克隆 T 细胞群体。
使用我们的面板，5.1%的淋巴增生性疾病相关异常发现病例显示两种异常（克隆）淋巴样和/或浆细胞群体。 © 2016 年国际临床细胞遗传学学会。
